Research Summaries

The FDA approved Bizengri for adults with advanced, unresectable, or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, providing a new targeted option for an ultra-rare and...

In this expert interview, W. Clay Jackson, MD, DipTh, discusses why deprescribing should be approached through shared decision-making, careful medication review, and attention to each patient’s current...

phase 3 RCT found mRNA-1010 superior to standard-dose vaccines for RT-PCR–confirmed influenza-like illness in adults ≥50.

Phase 3 data evaluated whether relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer.

Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms. ...

In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.

Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC, previews practical guidance on recognizing, differentiating, and treating anxiety disorders in primary care, including trauma-related conditions, physical symptom...

In this video, Brittany Albright, MD, discusses why primary care clinicians are often the first line of defense in recognizing and treating anxiety disorders. She reviews practical strategies for screening,...

In phase 1/2 BRUIN, most patients with CLL/SLL or MCL had stable or improved PROs during pirtobrutinib treatment.

Dr. William Schaffner, MD, reviews evolving adult vaccination guidance and key opportunities to prevent severe disease in clinical practice.